Effects of short-term fasting on cancer treatment

Stefanie de Groot, Hanno Pijl, Jacobus J M van der Hoeven, Judith R Kroep, Stefanie de Groot, Hanno Pijl, Jacobus J M van der Hoeven, Judith R Kroep

Abstract

Growing preclinical evidence shows that short-term fasting (STF) protects from toxicity while enhancing the efficacy of a variety of chemotherapeutic agents in the treatment of various tumour types. STF reinforces stress resistance of healthy cells, while tumor cells become even more sensitive to toxins, perhaps through shortage of nutrients to satisfy their needs in the context of high proliferation rates and/or loss of flexibility to respond to extreme circumstances. In humans, STF may be a feasible approach to enhance the efficacy and tolerability of chemotherapy. Clinical research evaluating the potential of STF is in its infancy. This review focuses on the molecular background, current knowledge and clinical trials evaluating the effects of STF in cancer treatment. Preliminary data show that STF is safe, but challenging in cancer patients receiving chemotherapy. Ongoing clinical trials need to unravel if STF can also diminish toxicity and increase efficacy of chemotherapeutic regimes in daily practice.

Keywords: Chemotherapy; Differential stress resistance; Differential stress sensitization; Fasting-mimicking diet; Short-term fasting; Toxicity.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schematic overview of differential effects of short-term fasting on healthy and cancer cells. Abbreviations: STF; short term fasting, IGF-1: insulin growth factor-1.

References

    1. Dirx MJ, Zeegers MP, Dagnelie PC, van den Bogaard T, van den Brandt PA. Energy restriction and the risk of spontaneous mammary tumors in mice: a meta-analysis. Int J Cancer. 2003;106(5):766–770. doi: 10.1002/ijc.11277.
    1. TANNENBAUM A, SILVERSTONE H. Effect of limited food intake on survival of mice bearing spontaneous mammary carcinoma and on the incidence of lung metastases. Cancer Res. 1953;13(7:1):532–6.
    1. De Lorenzo MS, Baljinnyam E, Vatner DE, Abarzua P, Vatner SF, Rabson AB. Caloric restriction reduces growth of mammary tumors and metastases. Carcinogenesis. 2011;32(9):1381–1387. doi: 10.1093/carcin/bgr107.
    1. Mai V, Colbert LH, Berrigan D, Perkins SN, Pfeiffer R, Lavigne JA, et al. Calorie restriction and diet composition modulate spontaneous intestinal tumorigenesis in Apc(min) mice through different mechanisms. Cancer Res. 2003;63(8):1752–1755.
    1. Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115147. doi: 10.1371/journal.pone.0115147.
    1. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325(5937):201–204. doi: 10.1126/science.1173635.
    1. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346–1353. doi: 10.1016/S0140-6736(04)16044-3.
    1. Ravussin E, Redman LM, Rochon J, Das SK, Fontana L, Kraus WE, et al. A 2-year randomized controlled trial of human caloric restriction: feasibility and effects on predictors of health span and longevity. J Gerontol A Biol Sci Med Sci. 2015;70(9):1097–1104. doi: 10.1093/gerona/glv057.
    1. Walford RL, Mock D, Verdery R, MacCallum T. Calorie restriction in biosphere 2: alterations in physiologic, hematologic, hormonal, and biochemical parameters in humans restricted for a 2-year period. J Gerontol A Biol Sci Med Sci. 2002;57(6):B211–B224. doi: 10.1093/gerona/57.6.B211.
    1. Racette SB, Weiss EP, Villareal DT, Arif H, Steger-May K, Schechtman KB, et al. One year of caloric restriction in humans: feasibility and effects on body composition and abdominal adipose tissue. J Gerontol A Biol Sci Med Sci. 2006;61(9):943–950. doi: 10.1093/gerona/61.9.943.
    1. Masoro EJ. Overview of caloric restriction and ageing. Mech Ageing Dev. 2005;126(9):913–922. doi: 10.1016/j.mad.2005.03.012.
    1. Lee C., Raffaghello L., Brandhorst S., Safdie F. M., Bianchi G., Martin-Montalvo A., Pistoia V., Wei M., Hwang S., Merlino A., Emionite L., de Cabo R., Longo V. D. Fasting Cycles Retard Growth of Tumors and Sensitize a Range of Cancer Cell Types to Chemotherapy. Science Translational Medicine. 2012;4(124):124ra27–124ra27. doi: 10.1126/scitranslmed.3003293.
    1. Safdie F, Brandhorst S, Wei M, Wang W, Lee C, Hwang S, et al. Fasting enhances the response of glioma to chemo- and radiotherapy. PLoS One. 2012;7(9):e44603. doi: 10.1371/journal.pone.0044603.
    1. Bianchi G, Martella R, Ravera S, Marini C, Capitanio S, Orengo A, et al. Fasting induces anti-Warburg effect that increases respiration but reduces ATP-synthesis to promote apoptosis in colon cancer models. Oncotarget. 2015;6(14):11806–11819. doi: 10.18632/oncotarget.3688.
    1. Shim HS, Wei M, Brandhorst S, Longo VD. Starvation promotes REV1 SUMOylation and p53-dependent sensitization of melanoma and breast cancer cells. Cancer Res. 2015;75(6):1056–1067. doi: 10.1158/0008-5472.CAN-14-2249.
    1. Di Biase S, Longo VD. Fasting-induced differential stress sensitization in cancer treatment. Mol Cell Oncol. 2016;3(3):e1117701. doi: 10.1080/23723556.2015.1117701.
    1. Di Biase S, Shim HS, Kim KH, Vinciguerra M, Rappa F, Wei M, et al. Fasting regulates EGR1 and protects from glucose- and dexamethasone-dependent sensitization to chemotherapy. PLoS Biol. 2017;15(3):e2001951. doi: 10.1371/journal.pbio.2001951.
    1. Brandhorst S, Wei M, Hwang S, Morgan TE, Longo VD. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression. Exp Gerontol. 2013;48(10):1120–1128. doi: 10.1016/j.exger.2013.02.016.
    1. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A. 2008;105(24):8215–8220. doi: 10.1073/pnas.0708100105.
    1. Huisman SA, Bijman-Lagcher W, IJzermans JN, Smits R, de Bruin RW. Fasting protects against the side effects of irinotecan but preserves its anti-tumor effect in Apc15lox mutant mice. Cell Cycle. 2015;14(14):2333–2339. doi: 10.1080/15384101.2015.1044170.
    1. Tinkum KL, Stemler KM, White LS, Loza AJ, Jeter-Jones S, Michalski BM, et al. Fasting protects mice from lethal DNA damage by promoting small intestinal epithelial stem cell survival. Proc Natl Acad Sci U S A. 2015;112(51):E7148–E7E54.
    1. Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, et al. Prolonged fasting reduces IGF-1/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell. 2014;14(6):810–823. doi: 10.1016/j.stem.2014.04.014.
    1. Huisman SA, de BP, Ghobadi Moghaddam-Helmantel IM, IJzermans JN, Wiemer EA, Mathijssen RH, et al. Fasting protects against the side-effects of irinotecan treatment but does not abrogate anti-tumor activity in mice. Br. J Pharmacol. 2015.
    1. Franny Jongbloed SAH, Harry van Steeg, Jeroen L.A. Pennings, Jan N.M. IJzermans, Martijn E.T. Dollé and Ron W.F. de Bruin. The transcriptomic response to irinotecan in colon carcinoma bearing mice preconditioned by fasting. Oncotarget. 2019.
    1. Schumacher B, Garinis GA, Hoeijmakers JH. Age to survive: DNA damage and aging. Trends Genet. 2008;24(2):77–85. doi: 10.1016/j.tig.2007.11.004.
    1. Kerndt PR, Naughton JL, Driscoll CE, Loxterkamp DA. Fasting: the history, pathophysiology and complications. West J Med. 1982;137(5):379–399.
    1. Caccialanza R, De Lorenzo F, Gianotti L, Zagonel V, Gavazzi C, Farina G, et al. Nutritional support for cancer patients: still a neglected right? Support Care Cancer. 2017;25(10):3001–3004. doi: 10.1007/s00520-017-3826-1.
    1. Caccialanza R, Aprile G, Cereda E, Pedrazzoli P. Fasting in oncology: a word of caution. Nat Rev Cancer. 2019.
    1. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48. doi: 10.1016/j.clnu.2016.07.015.
    1. Arends J, Baracos V, Bertz H, Bozzetti F, Calder PC, Deutz NEP, et al. ESPEN expert group recommendations for action against cancer-related malnutrition. Clin Nutr. 2017;36(5):1187–1196. doi: 10.1016/j.clnu.2017.06.017.
    1. Bishop NA, Guarente L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet. 2007;8(11):835–844. doi: 10.1038/nrg2188.
    1. Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. Science. 2010;328(5976):321–326. doi: 10.1126/science.1172539.
    1. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science. 1996;273(5271):59–63. doi: 10.1126/science.273.5271.59.
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
    1. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308. doi: 10.1016/j.ccr.2012.02.014.
    1. D'Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, et al. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget. 2015.
    1. Shi Y, Felley-Bosco E, Marti TM, Orlowski K, Pruschy M, Stahel RA. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin. BMC Cancer. 2012;12:571. doi: 10.1186/1471-2407-12-571.
    1. Saleh AD, Simone BA, Palazzo J, Savage JE, Sano Y, Dan T, et al. Caloric restriction augments radiation efficacy in breast cancer. Cell Cycle. 2013;12(12):1955–1963. doi: 10.4161/cc.25016.
    1. Caffa Irene, Longo Valter D., Nencioni Alessio. Fasting plus tyrosine kinase inhibitors in cancer. Aging. 2015;7(12):1026–1027. doi: 10.18632/aging.100857.
    1. Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, et al. Caloric restriction mimetics enhance anticancer Immunosurveillance. Cancer Cell. 2016;30(1):147–160. doi: 10.1016/j.ccell.2016.05.016.
    1. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocr Rev. 1994;15(1):80–101.
    1. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70(4):1564–1572. doi: 10.1158/0008-5472.CAN-09-3228.
    1. Hursting SD, Lavigne JA, Berrigan D, Donehower LA, Davis BJ, Phang JM, et al. Diet-gene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr. 2004;134(9):2482S–2486S. doi: 10.1093/jn/134.9.2482S.
    1. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011;30(30):3305–3316. doi: 10.1038/onc.2011.91.
    1. Kirkwood TB, Shanley DP. Food restriction, evolution and ageing. Mech Ageing Dev. 2005;126(9):1011–1016. doi: 10.1016/j.mad.2005.03.021.
    1. Kirkwood TL, Kapahi P, Shanley DP. Evolution, stress, and longevity. J Anat. 2000;197(Pt 4):587–590. doi: 10.1046/j.1469-7580.2000.19740587.x.
    1. Heilbronn LK, Ravussin E. Calorie restriction and aging: review of the literature and implications for studies in humans. Am J Clin Nutr. 2003;78(3):361–369. doi: 10.1093/ajcn/78.3.361.
    1. Murray MJ, Murray AB. Anorexia of infection as a mechanism of host defense. Am J Clin Nutr. 1979;32(3):593–596. doi: 10.1093/ajcn/32.3.593.
    1. Exton MS. Infection-induced anorexia: active host defence strategy. Appetite. 1997;29(3):369–383. doi: 10.1006/appe.1997.0116.
    1. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, et al. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomark Prev. 2003;12(2):84–89.
    1. Prisco M, Romano G, Peruzzi F, Valentinis B, Baserga R. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res. 1999;31(2–3):80–89. doi: 10.1055/s-2007-978703.
    1. Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO. Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. Aging Cell. 2008;7(5):681–687. doi: 10.1111/j.1474-9726.2008.00417.x.
    1. Belfiore A, Malaguarnera R, Vella V, Lawrence MC, Sciacca L, Frasca F, et al. Insulin receptor isoforms in physiology and disease: an updated view. Endocr Rev. 2017;38(5):379–431. doi: 10.1210/er.2017-00073.
    1. Ketelslegers JM, Maiter D, Maes M, Underwood LE, Thissen JP. Nutritional regulation of insulin-like growth factor-I. Metabolism. 1995;44(10 Suppl 4):50–57. doi: 10.1016/0026-0495(95)90221-X.
    1. Henning PC, Scofield DE, Rarick KR, Pierce JR, Staab JS, Lieberman HR, et al. Effects of acute caloric restriction compared to caloric balance on the temporal response of the IGF-I system. Metabolism. 2013;62(2):179–187. doi: 10.1016/j.metabol.2012.07.004.
    1. Snel M, Wijngaarden MA, Bizino MB, van der Grond J, Teeuwisse WM, van Buchem MA, et al. Food cues do not modulate the neuroendocrine response to a prolonged fast in healthy men. Neuroendocrinology. 2012;96(4):285–293. doi: 10.1159/000336500.
    1. Beauloye V, Willems B. de C, V, frank SJ, Edery M, Thissen JP. Impairment of liver GH receptor signaling by fasting. Endocrinology. 2002;143(3):792–800. doi: 10.1210/endo.143.3.8692.
    1. Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab. 2000;85(12):4712–4720.
    1. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999;96(13):7324–7329. doi: 10.1073/pnas.96.13.7324.
    1. Anzo M, Cobb LJ, Hwang DL, Mehta H, Said JW, Yakar S, et al. Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression. Cancer Res. 2008;68(9):3342–3349. doi: 10.1158/0008-5472.CAN-07-3165.
    1. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62(4):1030–1035.
    1. Kawaguchi T, Takemura G, Kanamori H, Takeyama T, Watanabe T, Morishita K, et al. Prior starvation mitigates acute doxorubicin cardiotoxicity through restoration of autophagy in affected cardiomyocytes. Cardiovasc Res. 2012;96(3):456–465. doi: 10.1093/cvr/cvs282.
    1. Withers SS, Kass PH, Rodriguez CO, Jr., Skorupski KA, O'Brien D, Guerrero TA, et al. , Fasting Reduces the Incidence of Delayed-Type Vomiting Associated with Doxorubicin Treatment in Dogs with Lymphoma. Transl. Oncol. 2014.
    1. Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer. 2013;20(1):R1–R17. doi: 10.1530/ERC-12-0324.
    1. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature. 2009;458(7239):725–731. doi: 10.1038/nature07782.
    1. Zhang Y, Moerkens M, Ramaiahgari S, de BH, Price L, Meerman J, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 2011;13(3):R52.
    1. de Groot S, Charehbili A, van Laarhoven HW, Mooyaart AL, Dekker-Ensink NG, van de Ven S, et al. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010–01). Breast Cancer Res. 2016;18(1):3.
    1. S de Groot RL, MJ Welters, I Ehsan, MP Vreeswijk, VT Smit, H de Graaf, JB Heijns, JE Portielje, AJ van de Wouw, AL Imholz, LW Kessels, S Vrijaldenhoven, A Baars, E Meershoek-Klein Kranenbarg, M Duijm-de Carpentier, E van Leeuwen-Stok, H Putter, VD Longo, JJ van der Hoeven, JW Nortier, H Pijl and JR Kroep. Abstract P1–15-20: DIetary REstriction as an adjunct to neoadjuvant ChemoTherapy for HER2-negative breast cancer: Final results from the DIRECT trial (BOOG 2013–04). American Association for Cancer Research. 2019.
    1. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res. 2008;68(13):5492–5499. doi: 10.1158/0008-5472.CAN-07-6721.
    1. Hardie DG. AMP-activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans. 2011;39(1):1–13. doi: 10.1042/BST0390001.
    1. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011;13(9):1016–1023. doi: 10.1038/ncb2329.
    1. Mizushima N. Autophagy: process and function. Genes Dev. 2007;21(22):2861–2873. doi: 10.1101/gad.1599207.
    1. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell. 2010;40(2):280–293. doi: 10.1016/j.molcel.2010.09.023.
    1. Vidal AP, Andrade BM, Vaisman F, Cazarin J, Pinto LF, Breitenbach MM, et al. AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer. Eur J Endocrinol. 2013;169(4):521–528. doi: 10.1530/EJE-13-0284.
    1. Zadra G, Batista JL, Loda M. Dissecting the dual role of AMPK in Cancer: from experimental to human studies. Mol Cancer Res. 2015;13(7):1059–1072. doi: 10.1158/1541-7786.MCR-15-0068.
    1. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, et al. Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer. 2009;9:307. doi: 10.1186/1471-2407-9-307.
    1. Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell. 2013;153(5):1064–1079. doi: 10.1016/j.cell.2013.04.055.
    1. Zheng L, Yang W, Wu F, Wang C, Yu L, Tang L, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma. Clin Cancer Res. 2013;19(19):5372–5380. doi: 10.1158/1078-0432.CCR-13-0203.
    1. Wang L, Shang Z, Zhou Y, Hu X, Chen Y, Fan Y, et al. Autophagy mediates glucose starvation-induced glioblastoma cell quiescence and chemoresistance through coordinating cell metabolism, cell cycle, and survival. Cell Death Dis. 2018;9(2):213. doi: 10.1038/s41419-017-0242-x.
    1. Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, et al. Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res. 2007;67(20):9677–9684. doi: 10.1158/0008-5472.CAN-07-1462.
    1. Petibone DM, Majeed W, Casciano DA. Autophagy function and its relationship to pathology, clinical applications, drug metabolism and toxicity. J Appl Toxicol. 2017;37(1):23–37. doi: 10.1002/jat.3393.
    1. van Niekerk G, Hattingh SM, Engelbrecht AM. Enhanced therapeutic efficacy in Cancer patients by short-term fasting: the autophagy connection. Front Oncol. 2016;6:242.
    1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11–20. doi: 10.1016/j.cmet.2007.10.002.
    1. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033. doi: 10.1126/science.1160809.
    1. Lankelma J, Kooi B, Krab K, Dorsman JC, Joenje H, Westerhoff HV. A reason for intermittent fasting to suppress the awakening of dormant breast tumors. Biosystems. 2015;127:1–6. doi: 10.1016/j.biosystems.2014.11.001.
    1. Kusuoka O, Fujiwara-Tani R, Nakashima C, Fujii K, Ohmori H, Mori T, et al. Intermittent calorie restriction enhances epithelial-mesenchymal transition through the alteration of energy metabolism in a mouse tumor model. Int J Oncol. 2018;52(2):413–423.
    1. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv. 2007;7(3):147–156. doi: 10.1124/mi.7.3.6.
    1. Veech RL. Ketone ester effects on metabolism and transcription. J Lipid Res. 2014;55(10):2004–2006. doi: 10.1194/jlr.R046292.
    1. Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32. doi: 10.1016/j.ejca.2010.10.013.
    1. Marij J. Welters, Tetje C. van der Sluis, Hélène van Meir, Nikki M. Loof, Vanessa J. van Ham, Suzanne van Duikeren et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T-cell responses. Sci Transl Med. 2016.
    1. Brandhorst S, Choi IY, Wei M, Cheng CW, Sedrakyan S, Navarrete G, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and Healthspan. Cell Metab. 2015;22(1):86–99. doi: 10.1016/j.cmet.2015.05.012.
    1. Wing EJ, Stanko RT, Winkelstein A, Adibi SA. Fasting-enhanced immune effector mechanisms in obese subjects. Am J Med. 1983;75(1):91–96. doi: 10.1016/0002-9343(83)91172-5.
    1. Englert JM, Powell JD. Hunger pains: stimulating the appetite of the immune system for Cancer. Cancer Cell. 2016;30(1):13–15. doi: 10.1016/j.ccell.2016.06.019.
    1. Di Biase S, Lee C, Brandhorst S, Manes B, Buono R, Cheng CW, et al. Fasting-mimicking diet reduces HO-1 to promote T cell-mediated tumor cytotoxicity. Cancer Cell. 2016;30(1):136–146. doi: 10.1016/j.ccell.2016.06.005.
    1. Jensen TL, Kiersgaard MK, Sorensen DB, Mikkelsen LF. Fasting of mice: a review. Lab Anim. 2013;47(4):225–240. doi: 10.1177/0023677213501659.
    1. Bhaskaran K, Douglas I, Forbes H. dos-Santos-Silva I, Leon DA, Smeeth L. body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384(9945):755–765. doi: 10.1016/S0140-6736(14)60892-8.
    1. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14. doi: 10.1093/annonc/mdu042.
    1. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009;124(10):2416–2429. doi: 10.1002/ijc.24202.
    1. Endogenous H. Breast Cancer collaborative G, key TJ, Appleby PN, reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530–542. doi: 10.1016/S1470-2045(10)70095-4.
    1. Ferroni P, Riondino S, Laudisi A, Portarena I, Formica V, Alessandroni J, et al. Pretreatment insulin levels as a prognostic factor for breast Cancer progression. Oncologist. 2016;21(9):1041–1049. doi: 10.1634/theoncologist.2015-0462.
    1. Duggan C, Wang CY, Neuhouser ML, Xiao L, Smith AW, Reding KW, et al. Associations of insulin-like growth factor and insulin-like growth factor binding protein-3 with mortality in women with breast cancer. Int J Cancer. 2013;132(5):1191–1200. doi: 10.1002/ijc.27753.
    1. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB, 3rd, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21(3):433–440. doi: 10.1200/JCO.2003.07.125.
    1. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27(7):1082–1086. doi: 10.1200/JCO.2008.19.1098.
    1. van Kruijsdijk RC, van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomark Prev. 2009;18(10):2569–2578. doi: 10.1158/1055-9965.EPI-09-0372.
    1. Vella Veronica, Milluzzo Agostino, Scalisi Nunzio, Vigneri Paolo, Sciacca Laura. Insulin Receptor Isoforms in Cancer. International Journal of Molecular Sciences. 2018;19(11):3615. doi: 10.3390/ijms19113615.
    1. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab. 2008;22(4):625–638. doi: 10.1016/j.beem.2008.08.004.
    1. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW., Jr Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796–1808. doi: 10.1172/JCI200319246.
    1. Johnstone AM. Fasting - the ultimate diet? Obes Rev. 2007;8(3):211–222. doi: 10.1111/j.1467-789X.2006.00266.x.
    1. Folin O, Denis W. On starvation and obesity, with special reference to acidosis. J Biol Chem. 1915;21:183–192.
    1. Stewart WK, Fleming LW. Features of a successful therapeutic fast of 382 days' duration. Postgrad Med J. 1973;49(569):203–209. doi: 10.1136/pgmj.49.569.203.
    1. Thomson TJ, Runcie J, Miller V. Treatment of obesity by total fasting for up to 249 days. Lancet. 1966;2(7471):992–996. doi: 10.1016/S0140-6736(66)92925-4.
    1. BLOOM WL. Fasting as an introduction to the treatment of obesity. Metabolism. 1959;8(3):214–220.
    1. Drenick Ernst J., Smith Roger. Weight Reduction by Prolonged Starvation. Postgraduate Medicine. 1964;36(6):A-95-A-100. doi: 10.1080/00325481.1964.11695378.
    1. Franc¸oise Wilhelmi de Toledo FG, Audrey Bergouignan, , Stefan Drinda AM. Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study including 1422 subjects. PLoS One. 2019.
    1. Spencer IO. Death during therapeutic starvation for obesity. Lancet. 1968;1(7555):1288–1290. doi: 10.1016/S0140-6736(68)92299-X.
    1. Cubberley Peter T., Polster Sheldon A., Schulman Charles L. Lactic Acidosis and Death after the Treatment of Obesity by Fasting. New England Journal of Medicine. 1965;272(12):628–630. doi: 10.1056/NEJM196503252721208.
    1. Runcie J, Thomson TJ. Prolonged starvation--a dangerous procedure? Br Med J. 1970;3(5720):432–435. doi: 10.1136/bmj.3.5720.432.
    1. Brazg J, Ruest A, Law S, Bosoy D. A therapeutic fast for lymphoma resulting in Wernicke encephalopathy. J Emerg Med. 2015;49(4):471–474. doi: 10.1016/j.jemermed.2015.03.022.
    1. Douillard C, Mention K, Dobbelaere D, Wemeau JL, Saudubray JM, Vantyghem MC. Hypoglycaemia related to inherited metabolic diseases in adults. Orphanet J Rare Dis. 2012;7:26. doi: 10.1186/1750-1172-7-26.
    1. Goldhamer AC, Lisle DJ, Sultana P, Anderson SV, Parpia B, Hughes B, et al. Medically supervised water-only fasting in the treatment of borderline hypertension. J Altern Complement Med. 2002;8(5):643–650. doi: 10.1089/107555302320825165.
    1. Cahill GF, Jr, Owen OE. Starvation and survival. Trans Am Clin Climatol Assoc. 1968;79:13–20.
    1. Michalsen A, Hoffmann B, Moebus S, Backer M, Langhorst J, Dobos GJ. Incorporation of fasting therapy in an integrative medicine ward: evaluation of outcome, safety, and effects on lifestyle adherence in a large prospective cohort study. J Altern Complement Med. 2005;11(4):601–607. doi: 10.1089/acm.2005.11.601.
    1. Han K, Nguyen A, Traba J, Yao X, Kaler M, Huffstutler RD, et al. A pilot study to investigate the immune-modulatory effects of fasting in steroid-naive mild asthmatics. J Immunol. 2018;201(5):1382–1388. doi: 10.4049/jimmunol.1800585.
    1. Wei Min, Brandhorst Sebastian, Shelehchi Mahshid, Mirzaei Hamed, Cheng Chia Wei, Budniak Julia, Groshen Susan, Mack Wendy J., Guen Esra, Di Biase Stefano, Cohen Pinchas, Morgan Todd E., Dorff Tanya, Hong Kurt, Michalsen Andreas, Laviano Alessandro, Longo Valter D. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Science Translational Medicine. 2017;9(377):eaai8700. doi: 10.1126/scitranslmed.aai8700.
    1. Zhan C, Dai X, Shen G, Lu X, Wang X, Lu L, et al. Preoperative short-term fasting protects liver injury in patients undergoing hepatectomy. Ann Transl Med. 2018;6(23):449. doi: 10.21037/atm.2018.10.64.
    1. Grundmann F, Muller RU, Reppenhorst A, Hulswitt L, Spath MR, Kubacki T, et al. Preoperative Short-Term Calorie Restriction for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized, Controlled, Open-Label, Pilot Trial. J Am Heart Assoc. 2018;7(6).
    1. Cahill G, Jr, Felig P, Owen O, Wahren J. Metabolic adaptation to prolonged starvation in man. Nord Med. 1970;83(3):89.
    1. Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988;81(4):968–975. doi: 10.1172/JCI113450.
    1. Norrelund H. The metabolic role of growth hormone in humans with particular reference to fasting. Growth Hormon IGF Res. 2005;15(2):95–122. doi: 10.1016/j.ghir.2005.02.005.
    1. Moller L, Dalman L, Norrelund H, Billestrup N, Frystyk J, Moller N, et al. Impact of fasting on growth hormone signaling and action in muscle and fat. J Clin Endocrinol Metab. 2009;94(3):965–972. doi: 10.1210/jc.2008-1385.
    1. de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC. Cancer. 2015;15:652.
    1. Maccario M, Aimaretti G, Grottoli S, Gauna C, Tassone F, Corneli G, et al. Effects of 36 hour fasting on GH/IGF-I axis and metabolic parameters in patients with simple obesity. Comparison with normal subjects and hypopituitary patients with severe GH deficiency. Int. J Obes Relat Metab Disord. 2001;25(8):1233–1239. doi: 10.1038/sj.ijo.0801671.
    1. Cotterill Andrew M., Holly Jeffrey M. P., Wass John A. H. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting. Clinical Endocrinology. 1993;39(3):357–362. doi: 10.1111/j.1365-2265.1993.tb02377.x.
    1. Boelen A, Wiersinga WM, Fliers E. Fasting-induced changes in the hypothalamus-pituitary-thyroid axis. Thyroid. 2008;18(2):123–129. doi: 10.1089/thy.2007.0253.
    1. Badar T, Ismail A, AlShanqeeti A. Safety and Feasability of Muslim Fasting While Receiving Chemotherapy. IOSR Journal of Pharmacy. 2014.
    1. Safdie Fernando M., Dorff Tanya, Quinn David, Fontana Luigi, Wei Min, Lee Changhan, Cohen Pinchas, Longo Valter D. Fasting and cancer treatment in humans: A case series report. Aging. 2009;1(12):988–1007. doi: 10.18632/aging.100114.
    1. Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016;16:360. doi: 10.1186/s12885-016-2370-6.
    1. Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. 2018;18(1):476. doi: 10.1186/s12885-018-4353-2.
    1. Raffaghello L, Safdie F, Bianchi G, Dorff T, Fontana L, Longo VD. Fasting and differential chemotherapy protection in patients. Cell Cycle. 2010;9(22):4474–4476. doi: 10.4161/cc.9.22.13954.
    1. Bouhlel E, Zaouali M, Miled A, Tabka Z, Bigard X, Shephard R. Ramadan fasting and the GH/IGF-1 axis of trained men during submaximal exercise. Ann Nutr Metab. 2008;52(4):261–266. doi: 10.1159/000140517.
    1. Inder WJ, Jang C, Obeyesekere VR, Alford FP. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1--implications for steroid-induced myopathy. Clin. Endocrinol. (Oxf). 2010;73(1):126–32.
    1. Veldhuis JD, Lizarralde G, Iranmanesh A. Divergent effects of short term glucocorticoid excess on the gonadotropic and somatotropic axes in normal men. J Clin Endocrinol Metab. 1992;74(1):96–102.
    1. Levolger S, van den Engel S, Ambagtsheer G, JNM IJ, de Bruin RWF. Caloric restriction is associated with preservation of muscle strength in experimental cancer cachexia. Aging (Albany NY) 2018;10(12):4213–4223. doi: 10.18632/aging.101724.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit